Trial Profile
Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Vestronidase alfa (Primary)
- Indications Mucopolysaccharidosis VII
- Focus Adverse reactions; Therapeutic Use
- Acronyms MPS VII DMP
- Sponsors Ultragenyx Pharmaceutical
- 10 Oct 2022 Planned number of patients changed from 35 to 50.
- 09 Jul 2020 Status changed from active, no longer recruiting to recruiting.
- 30 Mar 2020 Status changed from recruiting to active, no longer recruiting.